Found: 32
Select item for more details and to access through your institution.
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 370, doi. 10.1159/000515551
- By:
- Publication type:
- Article
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12225-6
- By:
- Publication type:
- Article
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.
- Published in:
- Internal & Emergency Medicine, 2024, v. 19, n. 4, p. 1151, doi. 10.1007/s11739-024-03578-8
- By:
- Publication type:
- Article
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data.
- Published in:
- Liver International, 2023, v. 43, n. 8, p. 1803, doi. 10.1111/liv.15641
- By:
- Publication type:
- Article
COVID‐19 and liver cancer clinical trials: Not everything is lost.
- Published in:
- Liver International, 2020, v. 40, n. 7, p. 1541, doi. 10.1111/liv.14532
- By:
- Publication type:
- Article
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211010937
- By:
- Publication type:
- Article
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy.
- Published in:
- Current Oncology, 2024, v. 31, n. 1, p. 547, doi. 10.3390/curroncol31010038
- By:
- Publication type:
- Article
Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2020, v. 146, n. 9, p. 2289, doi. 10.1007/s00432-020-03285-9
- By:
- Publication type:
- Article
Tumour burden score and immune‐related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors.
- Published in:
- Liver Cancer International, 2022, v. 3, n. 2, p. 63, doi. 10.1002/lci2.51
- By:
- Publication type:
- Article
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
- Published in:
- Oncologist, 2013, v. 18, n. 4, p. 379, doi. 10.1634/theoncologist.2012-0221
- By:
- Publication type:
- Article
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 2, p. 256, doi. 10.1002/cam4.592
- By:
- Publication type:
- Article
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.
- Published in:
- Drugs & Aging, 2021, v. 38, n. 7, p. 579, doi. 10.1007/s40266-021-00871-5
- By:
- Publication type:
- Article
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211010937
- By:
- Publication type:
- Article
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 7, p. 1179, doi. 10.1007/s00432-013-1429-x
- By:
- Publication type:
- Article
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1523, doi. 10.3390/cancers15051523
- By:
- Publication type:
- Article
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5834, doi. 10.3390/cancers14235834
- By:
- Publication type:
- Article
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients.
- Published in:
- Cancers, 2022, v. 14, n. 16, p. 3952, doi. 10.3390/cancers14163952
- By:
- Publication type:
- Article
Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders.
- Published in:
- Cancers, 2021, v. 13, n. 24, p. 6376, doi. 10.3390/cancers13246376
- By:
- Publication type:
- Article
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors.
- Published in:
- Cancers, 2021, v. 13, n. 22, p. 5665, doi. 10.3390/cancers13225665
- By:
- Publication type:
- Article
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
- Published in:
- Cancers, 2020, v. 12, n. 11, p. 3370, doi. 10.3390/cancers12113370
- By:
- Publication type:
- Article
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
- Published in:
- Cancers, 2020, v. 12, n. 7, p. 1862, doi. 10.3390/cancers12071862
- By:
- Publication type:
- Article
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
- Published in:
- Liver International, 2015, v. 35, n. 3, p. 1077, doi. 10.1111/liv.12636
- By:
- Publication type:
- Article
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 10, p. 1726, doi. 10.3390/jpm12101726
- By:
- Publication type:
- Article
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 2, p. N.PAG, doi. 10.3390/jpm12020204
- By:
- Publication type:
- Article
Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial.
- Published in:
- Molecular Imaging & Biology, 2020, v. 22, n. 5, p. 1446, doi. 10.1007/s11307-020-01489-6
- By:
- Publication type:
- Article
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 3, p. 359, doi. 10.1007/s11523-024-01060-1
- By:
- Publication type:
- Article
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.
- Published in:
- Targeted Oncology, 2024, v. 19, n. 2, p. 223, doi. 10.1007/s11523-024-01032-5
- By:
- Publication type:
- Article